All In MedTech

Device Trial Radar · NCT03065465

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

Randomized Controlled Trial (RCT) of Standard Endoscopic Hemostasis Compared to OVESCO for Severe Non-variceal UGI Hemorrhage

Last checked: Nov 20, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

65

Planned (sponsor's estimate)

Start

Nov 15, 2015

Primary completion

Dec 24, 2024

Study completion Feb 28, 2025

Sponsor

Lead sponsor
CURE Digestive Diseases Research CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of California, Los Angeles; VA Greater Los Angeles Healthcare System
First posted
Feb 28, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary specific aim is to perform a randomized controlled trial (RCT) to compare 30 day rebleed rates and other clinical outcomes of patients with severe, non-variceal upper GI hemorrhage (NVUGIH) - ulcers and Dieulafoy's lesions who are randomized as initial treatment with the new large over-the-scope-clip device for endoscopic hemostasis versus standard endoscopic hemostasis.

Conditions

  • Upper Gastrointestinal Hemorrhage

Interventions

  • Over-the-scope hemoclipping deviceDevice

    A endoscopic entrapment of tissue for control of bleeding or other applications.

  • Standard endoscopic treatmentOther

    Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rebleeding rate of non-variceal focal UGI lesionsTime frame: Outcome measure will be assessed at 30 days after participants are enrolled

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.